Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Nottingham academics develop new nanotechnology to treat brain tumours

04.06.2003


Academics at The University of Nottingham are developing new nanotechnology that could be used to treat brain tumours more effectively by reducing the serious side-effects associated with anti-cancer drugs.

A team led by Dr Martin Garnett in the School of Pharmaceutical Sciences has been awarded a £206,000 grant from the Biotechnology and Biological Sciences Research Council to continue investigations on the preparation of nanoparticles for delivering drugs to brain tumours.

Anti-cancer drugs are problematic because they can cause significant problems in other non-diseased areas of the body too, leading to nasty side effects for the patient. For brain tumours this is doubly difficult because, for most drugs, access to tumours can be even trickier.



The Nottingham academics are looking at changing the behaviour of anti-cancer molecules by putting them into tiny particles called nanoparticles, which are one ten-thousandth of a millimetre in diameter. These nanoparticles are made from polymers - molecules made from a long chain of chemical units. Using a ’’water-loving’’ polymer on the outside, and a ’’water-hating’’ polymer on the inside, allows the particles to assemble themselves with the drugs held in the centre of the nanoparticles.

Because of their size, these nanoparticles can only get out of the blood stream at the tumour and in the liver, preventing toxicity in many other tissues in the body.

The ’’water-loving’’ polymer on the surface of these particles greatly reduces the uptake of the drug to the liver, ensuring that it travels to the brain tumour more effectively. The polymers previously available for making nanoparticles were only capable of carrying small amounts of a drug and couldn’’t hold on to the drug for very long, leading the academics to design some new polymers in an attempt to overcome these problems.

Developing and testing new delivery systems for drugs can also be a problem because of the toxicity of anti-cancer drugs. The academics are overcoming this problem by using drugs that are used to treat the inflammation of the brain that accompanies brain tumours, but are much less harmful to the patient and easier for the researchers to work with.

The idea for this new technology first came as part of discussions within the University’’s Children’’s Brain Tumour Research Centre which involves a number of academics from different disciplines. Co-ordinated by Dr David Walker the centre investigates the causes and potential new treatments for brain tumours in children.

The project is part of a two-centre award from the BBSRC totalling £409,000 which involves the synthesis of new polymers by scientists Dr Gillian Hutcheon and Dr Sean Higgins at Liverpool John Moores University and the development of nanoparticles by Dr Garnett and colleague Dr Paraskevi Kallinteri at The University of Nottingham.

The new project builds on results from a previous BBSRC grant, which have shown that the new polymers have allowed the researchers to incorporate anti-inflammatory drugs into nanoparticles in much greater amounts than with previous polymers and that they also hold on to the drugs much more firmly.

A patent has been filed on the use of these polymers, which should help in the future development of these delivery systems, and the drug release properties of these polymers are now being investigated by research student Weina Meng, whose work has been partly funded by the Children’’s Brain Tumour Research Centre.

The new project will develop these polymers further to discover whether it is possible to incorporate a much wider variety of drugs, including toxic anti-cancer drugs, and also to demonstrate that they work well in test systems.

Dr Garnett said: "I am very pleased with the progress in this project so far. The new polymers have exceeded my expectations and the flexibility of the synthesis of these polymers offers hope that they should be suitable for delivering a wide range of drugs.

"While there is still a long road ahead, we hope that this work will lead to clinical trials of these delivery systems and, eventually, a reduction in the side effects that patients suffer as a result of being treated with anti-cancer drugs."

Lyn Heath-Harvey | alfa
Further information:
http://www.nottingham.ac.uk/public-affairs/index.html

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>